# US 2013/0251748 A1 · Use of outer membrane porin k36 protein (ompk36) in treatment/prevention/diagnosis of enterobacteriaceae infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251748 A1
- Document ID: US20130251748A1
- Status: Published application
- Kind: A1
- Application number: 13/545,492
- Filed: 2012-07-10
- Published: 2013-09-26
- Earliest claimed: 2012-03-23
- Assignees: National Defense Medical Center
- Inventors: Leung-Kei Siu; Feng-Yee Chang; Yung-Chung Lin; Chang-Phone Fung; Yip-Mei Liu; Jiun-Han Chen; Yu-Kuo Tsai; Pele Choi-Sing Chong; Chih-Hsiang Leng; Shih-Jen Liu; Hsin-Wei Chen
- Web page: https://patentgrep.com/patent/US20130251748A1

## CPC

- G01N 33/56916: {Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia}
- A61K 39/0266: {Klebsiella}
- A61P 31/04: Antibacterial agents
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- G01N 2333/245: Escherichia (G)
- G01N 2333/255: Salmonella (G)
- G01N 2333/26: Klebsiella (G)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or E. coli in central nervous system and/or peripheral blood circulation, which comprises administering an effective amount of an OmpK36/homologues or its derivatives to the mammal.

## Claims

### Claim 1

A method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or Escherichia coli in central nervous system and/or peripherial blood circulation, which comprises administering to the mammal an effective amount of an outer membrane porin K36 (OmpK36).

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the OmpK36 is obtained from Escherichia, Klebsiella pneumoniae or Salmonella typhi.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the antibody is polyclonal antibodies.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the mammal is human.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the OmpK36 is a recombinant OmpK36 or its homologues.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the OmpK36 is administrated at an amount of 0.0001% to 10% by weight of OmpK36.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the OmpK36 is administrated at an amount of 0.5% to 5% by weight of OmpK36.

### Claim 8

A method for the treatment or prevention of Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or Escherichia coli in central nervous system and/or peripherial blood circulation in a mammal, which comprises administering to the mammal an effective amount of an outer membrane porin K36 (OmpK36).

### Claim 9 (depends on 8)

The method as claimed in claim 8, wherein the OmpK36 is obtained form Escherichia coli, Klebsiella pneumoniae, or Salmonella typhi.

### Claim 10 (depends on 8)

The method as claimed in claim 8, wherein the mammal is human.

### Claim 11 (depends on 8)

The method as claimed in claim 8, wherein the OmpK36 is a recombinant OmpK36.

### Claim 12 (depends on 8)

The method as claimed in claim 8, wherein the OmpK36 is administrated orally or via intravenous injection.

### Claim 13 (depends on 12)

The method as claimed in claim 12, wherein the OmpK36 is administrated at an amount of 0.0001% to 10% by weight of OmpK36.

### Claim 14 (depends on 12)

The method as claimed in claim 12, wherein the OmpK36 is administrated at an amount of 0.5% to 5% by weight of OmpK36.

### Claim 15

A method for detecting or diagnosing bacterial infection caused by Klebsiella pneumoniae or Salmonella typhi in central nervous system and/or peripheral blood circulation in a mammal, which comprises coating a first specific anti-OmpK36 antibody onto a matrix surface that can immunospecifically bind to OmpK36 molecular in blood or OmpK36 on the bacterial cellular membrane; adding a specimen from peripheral blood circulation and/or central nervous system to the matrix, adding a second anti-OmpK36 antibody with a label; and detecting the binding of the anti-OmpK36 antibodies to the OmpK36 molecule or OmpK36 on the bacterial cellular membrane, wherein the binding results demonstrates that the mammal may suffer from the bacterial infection in the central nervous system and/or peripheral blood circulation; and wherein the OmpK36 is obtained from Klebsiella pneumoniae, Salmonella typhi, or Escherichia coli.

### Claim 16 (depends on 15)

The method as claimed in claim 15, wherein the mammal is human.

### Claim 17 (depends on 15)

The method as claimed in claim 15, wherein the matrix is ELISA plates or magnetic nano-particles.

### Claim 18 (depends on 15)

The method as claimed in claim 15, wherein the label is radioisotopes, fluorophores or chemilumiphores.
